-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised lanadelumab for
patients with hereditary angioedema (HAE) type 1 or 2.

HAE type 1 or 2 and listing dates

HAE is a rare inherited disorder characterised by recurrent episodes of
severe swelling (angioedema) mainly in the limbs, face, intestinal tract
or airway.

Listing date:

-   lanadelumab – 01 December 2021

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
